Moderate chronic kidney disease and left ventricular hypertrophy after aortic valve replacement for aortic valve stenosis

Journal of Thoracic and Cardiovascular Surgery

Volumn 139, Issue 4, 2010, Pages 881-886

  Benedetto, Umberto ^a   Melina, Giovanni ^a   Angeloni, Emiliano ^a   Refice, Simone ^a   Scafani, Gianluca ^a   Roscitano, Antonino ^a   Tonelli, Euclide ^a   Sinatra, Riccardo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; CHRONIC KIDNEY DISEASE; CONFOUNDING VARIABLE; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTHESIS; REMISSION;

AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; CHRONIC DISEASE; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MALE; MIDDLE AGED; REMISSION INDUCTION;

EID: 77949443084     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.05.041     Document Type: Article

References (20)

1. Mihaljevic T., Nowicki E.R., Rajeswaran J., Blackstone E.H., Lagazzi L., Thomas J., et al. Survival after valve replacement for aortic stenosis: implications for decision making. J Thorac Cardiovasc Surg 135 (2008) 1270-1278
2. Gaudino M., Alessandrini F., Glieca F., Luciani N., Cellini C., Pragliola C., et al. Survival after aortic valve replacement for aortic stenosis: does left ventricular mass regression have a clinical correlate?. Eur Heart J 26 (2005) 51-57
3. Tasca G., Mhagna Z., Perotti S., Centurini P.B., Sabatini T., Amaducci A., et al. Impact of patient-prosthesis mismatch on cardiac events and midterm mortality after aortic valve replacement in patients with pure aortic stenosis. Circulation 113 (2006) 570-576
4. Lund O., Emmertsen K., Dørup I., Jensen F.T., and Flø C. Regression of left ventricular hypertrophy during 10 years after valve replacement for aortic stenosis is related to the preoperative risk profile. Eur Heart J 24 (2003) 1437-1446
5. Hanayama N., Christakis G.T., Mallidi H.R., Rao V., Cohen G., Goldman B.S., et al. Determinants of incomplete left ventricular mass regression following aortic valve replacement for aortic stenosis. J Card Surg 20 (2005) 307-313
6. Perticone F., Maio R., Ruberto C., Cassano S., Tripepi G., Perticone M., et al. Kidney function and risk factors for left ventricular hypertrophy in untreated uncomplicated essential hypertension. Am J Kidney Dis 52 (2008) 74-84
7. Wang A.Y., Li P.K., Lui S.F., and Sanderson J.E. Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence?. Nephrology 9 (2004) 190-197
8. Giles P.D., and Fitzmaurice D.A. Formula estimation of glomerular filtration rate: have we gone wrong?. BMJ 334 (2007) 1198-1200
9. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., and Germano G. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25 (2007) 1751-1762
10. McKee P.A., Castelli W.P., McNamara P.M., and Kannel W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 (1971) 1441-1446
11. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A., Foster E., Pellikka P.A., et al. Recommendations for chamber quantification. Eur J Echocardiogr 7 (2006) 79-108
12. de Simone G., Daniels S.R., Devereux R.B., Meyer R.A., Roman M.J., de Divitiis O., et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and of the impact of overweight. J Am Coll Cardiol 19 (1992) 1550-1558
13. Zoccali C., Benedetto F.A., Mallamaci F., Tripepi G., Giacone G., Cataliotti A., et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12 (2001) 2768-2774
14. de Simone G., Devereux R.B., Ganau A., Hahn R.T., Saba P.S., Mureddu G.F., et al. Estimation of left ventricular chamber and stroke volume by limited M-Mode echocardiography and validation by two-dimensional and Doppler echocardiography. Am J Cardiol 78 (1996) 801-807
15. Verdecchia P., Angeli F., Achilli P., Castellani C., Broccatelli A., Gattobigio R., et al. Echocardiographic left ventricular hypertrophy in hypertension: marker for future events or mediator of events?. Curr Opin Cardiol 22 (2007) 329-334
16. Dahlof B. Effect of angiotensin II blockade on cardiac hypertrophy and remodeling: a review. J Hum Hypertens 9 suppl (1995) S37-S44
17. Baker K.M., Chernin M.I., Wixson S.K., and Aceto J.F. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol 28 (1990) H324-H332
18. Kupfahl C., Pink D., Friedrich K., Zurbrügg H.R., Neuss M., Warnecke C., et al. Angiotensin II directly increases transforming growth factor beta 1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res 46 (2000) 463-475
19. Matsukawa T., Gotoh E., Minamisawa K., Kihara M., Ueda S., Shionoiri H., et al. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 261 (1991) R690-R696
20. Salen F.N., Schirmer H., Sundsfjord J., and Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24 (2003) 2054-2060